Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 2/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752998 | 0.86 | L3MBTL1 (0.47) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL752621 | 0.86 | HCRTR1 (0.39) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL5813476 | 0.72 | HPGD (0.50) | ALDH1A1MAPTKDM4EPOLBHPGD | |
| SCHEMBL751790 | 0.70 | HCRTR2 (0.64) | MAPTHCRTR1HCRTR2 | |
| SCHEMBL752226 | 0.70 | HCRTR2 (0.53) | MEN1KMT2AHCRTR1HCRTR2 | |
| SCHEMBL17314463 | 0.70 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AMAPTEHMT2 | |
| SCHEMBL15818175 | 0.70 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AMAPTEHMT2 | |
| SCHEMBL15818177 | 0.70 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AMAPTEHMT2 | |
| SCHEMBL15818176 | 0.70 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AMAPTEHMT2 | |
| SCHEMBL698306 | 0.70 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AMAPTEHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430004-B1 | NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | claimed |
| US-8329706-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-11 | — | — | US | claimed |
| US-20120101111-A1 | NOVEL OXAZOLIDINONE DERIVIATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | claimed |
| CN-102414184-A | Novel oxazolidinone derivatives and their use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2012-04-11 | — | — | CN | claimed |
| EP-2430004-A2 | NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-21 | — | — | EP | claimed |
| WO-2010131192-A2 | NOVEL OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-18 | — | — | WO | claimed |
| EP-2430004-B1 | NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-8329706-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-11 | — | — | US | disclosed |
| US-20120101111-A1 | NOVEL OXAZOLIDINONE DERIVIATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | disclosed |
| CN-102414184-A | Novel oxazolidinone derivatives and their use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2012-04-11 | — | — | CN | disclosed |
| EP-2430004-A2 | NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010131192-A2 | NOVEL OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101111-A1 | NOVEL OXAZOLIDINONE DERIVIATIVES | HCRTR2, HCRTR1, NPY4R | ALDH1A1 715/4885MEN1 949/4885KMT2A 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.